Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to 228.31%.

  • Voyager Therapeutics' EBIT Margin fell 1723600.0% to 228.31% in Q3 2025 from the same period last year, while for Sep 2025 it was 446.84%, marking a year-over-year decrease of 4523900.0%. This contributed to the annual value of 104.11% for FY2024, which is 1529100.0% down from last year.
  • As of Q3 2025, Voyager Therapeutics' EBIT Margin stood at 228.31%, which was down 1723600.0% from 704.33% recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' EBIT Margin peaked at 1584.71% during Q4 2022, and registered a low of 3244.68% during Q1 2022.
  • For the 5-year period, Voyager Therapeutics' EBIT Margin averaged around 621.28%, with its median value being 393.62% (2021).
  • As far as peak fluctuations go, Voyager Therapeutics' EBIT Margin tumbled by -28510600bps in 2022, and later soared by 33263400bps in 2023.
  • Quarter analysis of 5 years shows Voyager Therapeutics' EBIT Margin stood at 20.31% in 2021, then skyrocketed by 7702bps to 1584.71% in 2022, then tumbled by -96bps to 60.03% in 2023, then crashed by -1116bps to 610.05% in 2024, then soared by 63bps to 228.31% in 2025.
  • Its last three reported values are 228.31% in Q3 2025, 704.33% for Q2 2025, and 533.74% during Q1 2025.